Ligand Pharmaceuticals Statistics
Total Valuation
LGNYZ has a market cap or net worth of 1.96 billion. The enterprise value is 1.76 billion.
| Market Cap | 1.96B |
| Enterprise Value | 1.76B |
Important Dates
The next estimated earnings date is Wednesday, August 6, 2025.
| Earnings Date | Aug 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.84% |
| Shares Change (QoQ) | +1.14% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 18.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 16.50 |
| PS Ratio | 10.80 |
| PB Ratio | 2.46 |
| P/TBV Ratio | 4.50 |
| P/FCF Ratio | 38.48 |
| P/OCF Ratio | 37.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 264.75, with an EV/FCF ratio of 34.47.
| EV / Earnings | -13.24 |
| EV / Sales | 9.67 |
| EV / EBITDA | 264.75 |
| EV / EBIT | n/a |
| EV / FCF | 34.47 |
Financial Position
The company has a current ratio of 5.27, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.27 |
| Quick Ratio | 4.46 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 0.09 |
| Interest Coverage | -4.42 |
Financial Efficiency
Return on equity (ROE) is -16.56% and return on invested capital (ROIC) is -1.29%.
| Return on Equity (ROE) | -16.56% |
| Return on Assets (ROA) | -1.14% |
| Return on Invested Capital (ROIC) | -1.29% |
| Return on Capital Employed (ROCE) | -1.96% |
| Revenue Per Employee | 2.67M |
| Profits Per Employee | -1.95M |
| Employee Count | 68 |
| Asset Turnover | 0.20 |
| Inventory Turnover | 4.37 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +372.97% in the last 52 weeks. The beta is 0.76, so LGNYZ's price volatility has been lower than the market average.
| Beta (5Y) | 0.76 |
| 52-Week Price Change | +372.97% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 54.39 |
| Average Volume (20 Days) | 33,663 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 9.98 |
Income Statement
In the last 12 months, LGNYZ had revenue of 181.49 million and -132.62 million in losses. Loss per share was -7.11.
| Revenue | 181.49M |
| Gross Profit | 102.91M |
| Operating Income | -16.63M |
| Pretax Income | -161.11M |
| Net Income | -132.62M |
| EBITDA | 18.16M |
| EBIT | -16.63M |
| Loss Per Share | -7.11 |
Balance Sheet
The company has 208.90 million in cash and 4.45 million in debt, giving a net cash position of 204.45 million.
| Cash & Cash Equivalents | 208.90M |
| Total Debt | 4.45M |
| Net Cash | 204.45M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 795.53M |
| Book Value Per Share | 41.27 |
| Working Capital | 250.63M |
Cash Flow
In the last 12 months, operating cash flow was 52.87 million and capital expenditures -1.93 million, giving a free cash flow of 50.94 million.
| Operating Cash Flow | 52.87M |
| Capital Expenditures | -1.93M |
| Free Cash Flow | 50.94M |
| FCF Per Share | n/a |
Margins
Gross margin is 56.70%, with operating and profit margins of -9.16% and -73.07%.
| Gross Margin | 56.70% |
| Operating Margin | -9.16% |
| Pretax Margin | -88.77% |
| Profit Margin | -73.07% |
| EBITDA Margin | 10.00% |
| EBIT Margin | -9.16% |
| FCF Margin | 28.07% |
Dividends & Yields
LGNYZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.84% |
| Shareholder Yield | n/a |
| Earnings Yield | -6.77% |
| FCF Yield | 2.60% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LGNYZ has an Altman Z-Score of 11.41.
| Altman Z-Score | 11.41 |
| Piotroski F-Score | n/a |